No retraction, correction or concern found when last checked on Oct 19, 2026.

The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance

Günther Schönrich, Martin J. Raftery

Frontiers in Cellular and Infection Microbiology · 2019 · Review · CC BY

doi:10.3389/fcimb.2019.00207

Abstract

Programmed cell death protein (PD-1) and its ligands play a fundamental role in the evasion of tumor cells from antitumor immunity. Less well appreciated is the fact that the PD-1/PD-L1 axis also regulates antiviral immune responses and is therefore modulated by a number of viruses. Upregulation of PD-1 and its ligands PD-L1 and PD-L2 is observed during acute virus infection and after infection with persistent viruses including important human pathogens such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV). Experimental evidence suggests that insufficient signaling through the PD-1 pathway promotes immunopathology during acute infection by exaggerating primary T cell responses. If chronic infection is established, however, high levels of PD-1 expression can have unfavorable immunological consequences. Exhaustion and suppression of antiviral immune responses can result in viral immune evasion. The role of the PD-1/PD-L1 axis during viral infections is further complicated by evidence that PD-L1 also mediates inflammatory effects in the acute phase of an immune response. In this review, we discuss the intricate interplay between viruses and the PD-1/PD-L1 axis.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1Programmed cell death 1 (PD-1, also known as CD279) was discovered by Tasuku Honjo et al. at Kyoto University from a screen of genes involved in programmed cell death (Ishida et al., ). PD-1 expression is rapidly induced after signaling through the T cell receptor (TCR) and modulated by cytokines (Agata et al.,; Yamazaki et al.,; Wherry et al.,; Chikuma et al.,; Terawaki et al.,; Ahn et al., ). Other types of immune cells such as B cells, natural killer (NK) cells, NKT cells, dendritic cells (DCs), and monocytes also express PD-1 (Sharpe et al.,; Keir et al., ).

2There is ample evidence that PD-1, a member of the immunoglobulin superfamily, regulates the magnitude and quality of T cell responses. It plays a pivotal role in the induction and maintenance of central as well as peripheral tolerance (Nishimura et al.,,; Wang et al.,; Okazaki and Honjo,; Francisco et al.,; Fife and Pauken, ). For example, antigen presentation by resting DCs induces peripheral CD8+ T cell tolerance by signaling through PD-1 on CD8+ T cells (Probst et al., ). In fact, PD-1 has been called a ‘rheostat’ that calibrates threshold, strength, and duration of T cell responses (Okazaki et al.,; Honda et al., ). PD-1 belongs to a group of structurally different surface molecules that function as co-inhibitory receptors during immune responses against pathogens and cancer (Attanasio and Wherry,; Hashimoto et al.,; Sharpe and Pauken, ). These molecules counterbalance co-stimulatory receptors on T cells such as CD28, which bind to CD80 and CD86 on professional APCs and facilitate T cell activation (Esensten et al., ).

3Clinical studies have shown that blocking the PD-1 pathway is effective against several types of cancer including melanoma, lymphoma, lung, and renal cancer (Sanmamed and Chen, ). This type of treatment is referred to as immune checkpoint therapy and the blocking reagents are called immune checkpoint-inhibitors (ICIs). Together with James P. Allison, who worked on another co-inhibitory receptor called cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4), Tasuku Honjo was awarded the Nobel Prize in Physiology or Medicine 2018 for the discovery of cancer therapy by inhibition of negative immune regulation (Wolchok, ).

4PD-1 interacts with the ligands PD-L1 (CD274; also called B7-H1) and PD-L2 (CD273; also called B7-DC), which show distinct expression patterns. In vitro, PD-1 inhibits T cell activation by recruiting Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) after interaction with its ligands on APCs (Chen and Flies,; Okazaki et al.,; Sharpe and Pauken, ). This is associated with dephopshorylation of crucial tyrosine residues within the CD3 complex and CD28. In virus-infected mice lacking SHP2 in T cells, however, PD-1 signaling is not impaired, suggesting the existence of redundant inhibitory pathways downstream of PD-1 (Rota et al., ).

5PD-L1 is expressed not only by all hematopoietic cells but also by many non-hematopoietic cell types such as endothelial cells and epithelial cells (Sharpe and Pauken, ). In contrast, PD-L2 expression is more restricted and can be induced on hematopoietic cells such as DCs, B cells, and monocytes/macrophages. Besides PD-1, there are other known interacting partners for PD-L1 and PD-L2. PD-L1 also binds to CD80 whereas PD-L2 uses RGM domain family member B (RGMB) as an alternative binding partner. Both types of interaction also inhibit immune responses (Butte et al.,; Xiao et al., ).

6Viruses have to overcome strong barriers to replicate in the hostile environment of their hosts (Virgin et al., ). An arsenal of weapons helps viruses to subvert antiviral immunity. This includes the exploitation of host inhibitory receptor signaling pathways (Ong et al., ). The impact of the PD-1/PD-L1 axis in chronic virus infections is well described whereas its role during the acute phase of viral infections is less clear (Brown et al.,; Attanasio and Wherry, ). However, whether virus-induced upregulation of PD-1 ligands represents a viral immune evasion strategy or an adaption of the host defense to minimize immunopathology is a moot point. In this review, we highlight the diverse roles of PD-1 and its ligands during virus infections and their implications for host-pathogen interaction.

The Role of the PD-1 Pathway in Acute Virus Infections

7In mice acutely infected with lymphocytic choriomeningitis virus (LCMV) strain Armstrong (LCMV Arm) PD-1 is rapidly upregulated on naïve virus-specific CD8+ T cells before they clonally expand (Ahn et al., ). In this model of acute LCMV infection, CD4+ T cells are not required for virus clearance, which occurs within 1–2 weeks after infection (Matloubian et al., ). Blockade of the PD-1 pathway at this stage further increases effector functions of CD8+ T cells by enhancing granzyme B expression and mechanistic Target of Rapamycin (mTOR) signaling. Consequently, virus elimination is accelerated although the total number of virus-specific CD8+ T cells does not change (Ahn et al., ). Similarly, the PD-1/PD-L axis inhibits the differentiation of CD8+ T lymphocytes into polyfunctional cytotoxic T cells during acute infection of mice with murine retrovirus (David et al., ). This implies that PD-1 negatively regulates the terminal differentiation of naïve CD8+ T cells into effector CD8+ T lymphocytes during acute virus infection.

8After virus clearance, PD-1 expression on virus-specific T cells returns to normal levels (Barber et al.,; Blattman et al., ). The expanded pool of virus-specific effector T lymphocytes contracts due to increased cell death and memory T cells arise from a subset of fate-permissive effector T cells (Akondy et al.,; Omilusik and Goldrath,; Youngblood et al., ). There are at least three major memory T cell subsets: central memory T cells (Tcm cells), effector memory T cells (Tem cells), and recently defined tissue-resident memory T cells (Trm cells). Tcm cells lack effector functions but express lymph node homing molecules and circulate through the blood and the secondary lymphoid organs (Sallusto et al., ). After stimulation, Tcm cells differentiate into Tem cells that lack lymph node homing molecules and continuously recirculate between blood, lymph and non-lymphoid tissues. Tem cells are bestowed with various effector functions (Sallusto et al., ). In contrast, Trm cells do not recirculate (Wakim et al.,; Gebhardt et al.,; Masopust et al., ) and express core phenotypic markers including co-inhibitory receptors such as PD-1 (Hombrink et al.,; Kumar et al.,; Pallett et al., ). Functionally, Trm cells participate in the first line of defense to viruses by establishing an antiviral state and recruiting circulating memory T cells to sites of viral infection (Schenkel et al.,,; Ariotti et al.,; Carbone and Gebhardt, ). Located in multiple anatomical sites including barrier tissue such as lung, skin and gut, Trm cells are indispensable for antiviral immunity and immunosurveillance (Shin,; Wu et al.,; Szabo et al., ). The functional role of the PD-1/PD-L1 axis for CD8+ Trm cells is unclear at the moment but it may prevent uncontrolled Trm activation and inflammation in virus-infected tissues and other inflammatory conditions. In accordance, blockade of PD-1 on Trm cells increases the severity of eczema in a mouse model of allergic contact dermatitis (Gamradt et al., ).

9Intriguingly, the number of memory precursor T cells increases if PD-1 is blocked by antibodies during acute LCMV infection, possibly due to faster virus elimination (Ahn et al., ). Virus-specific memory CD8+ T cells that develop after the elimination of LCMV persist without antigen and are capable of self-renewal due to homeostatic proliferation in response to IL-7 and IL-15 (Wherry et al.,; Surh and Sprent,; Abdelsamed et al., ). Although the blockade of the PD-1/PD-L1 axis in mice infected with LCMV Arm increases effector CD8+ T cell function, no excessive tissue damage is observed (Ahn et al., ). Similar to the LCMV strain WE (LCMV WE), LCMV Arm does not disseminate but instead is eliminated from infected laboratory mice after acute infection. In contrast, derivatives of LCMV Arm and LCMV WE (“clone 13” and “docile,” respectively) replicate more vigorously and persist (Matloubian et al.,; Welsh and Seedhom, ). These LCMV strains cause lethal immunopathology in mice deficient of the PD-1/PD-L1 axis (PD-L1 KO mice, PD-1 KO mice) during the acute phase of infection (Barber et al.,; Mueller et al.,; Frebel et al.,; Zinselmeyer et al.,; Shaabani et al., ). This is due to the killing of LCMV-infected vascular endothelium by CD8+ T cells resulting in vascular leakage with pulmonary edema and severe hypotension (Frebel et al., ). In a mouse model of acute viral hepatitis, the absence of PD-1 is associated not only with more rapid virus clearance but also with more severe hepatitis (Iwai et al., ). These results imply that the stimulation of the PD-1/PD-L1 axis during the acute phase of virus infection helps to adjust the strength and quality of the cytotoxic CD8+ T cell attack so that the good (virus elimination) and the bad (tissue damage) is balanced, preventing excessive tissue damage.

Virus-Driven PD-L1/2 Expression

10Many viruses increase PD-L1/2 expression on hematopoietic cells (Table 1) and non-hematopoietic cells (Table 2). PD-L1/2 expression is regulated by proinflammatory and anti-inflammatory signals (Sun et al., ). The promotor regions of PD-L1 and PD-L2, which are paralog genes, are differentially regulated although they show similarly arranged binding sites for transcription factors (Garcia-Diaz et al., ).

11Type I and type III interferons (IFNs) are important antiviral cytokines. They are induced early in virus-infected barrier tissue such as lung/gut epithelial cells and serve as the first line of antiviral defense (Okabayashi et al.,; Wack et al.,; Andreakos et al.,; Galani et al.,; Zanoni et al.,; Good et al.,; Lazear et al., ). Type I IFNs, which in humans include several IFN-α subtypes and IFN-β, increase PD-L1 expression but to a lesser extent than PD-L2 expression (Garcia-Diaz et al., ). PD-L2 responds equally well to IFN-γ (type II IFN) and IFN-β (Garcia-Diaz et al., ). IL-4 may be an even more potent inducer of PD-L2 (Loke and Allison, ) thus accounting for the presence of PD-L2 on monocyte-derived DCs generated in vitro. Blockade or absence of type I IFN signaling during chronic LCMV infection results in reduced PD-L1 expression despite enhanced viral replication (Teijaro et al.,; Wilson et al.,; Shaabani et al., ). Although type I IFNs moderately upregulate PD-L1 (Sun et al., ) they increase NK cytotoxicity and allow clonal expansion and memory formation of antiviral cytotoxic CD8+ T cells (Biron et al.,; Kolumam et al.,; Aichele et al., ). Type III IFNs signal through a unique heterodimeric receptor and induce the expression of antiviral IFN-stimulated genes (ISGs) similar to type I IFNs (Davidson et al., ). Intriguingly, type III IFNs do not upregulate PD-L1 (Raftery et al., ). Accordingly, in this early phase of acute infection the PD-1/PD-L1 axis does not inhibit antiviral immune cells.

12Recognition of viruses by pattern recognition receptors (PRRs) also upregulates PD-L1. TLR3 signaling in particular strongly increases PD-L1 levels on DCs (Pulko et al.,; Boes and Meyer-Wentrup,; Raftery et al., ) whereas RIG-I signaling alone has no significant effect (Raftery et al., ). Triggering of TLR3, which transmits downstream signals through the TIR-domain-containing adapter-inducing IFN-β (TRIF), also enhances PD-L1 on other cell types including endothelial cells (Cole et al., ) and epithelial cells (Tsuda et al., ). In accordance, virus-induced PD-L1 upregulation on neuronal cells is severely impaired in TLR3-deficient mice (Lafon et al., ). Recently, viral proteins inducing PD-L1/PD-L2 expression have been identified. For example, HIV Tat protein increases PD-L1 expression on DCs through TNF-α and TLR4 signaling (Planes et al., ). The HCV core protein in vitro induces strong PD-L1 upregulation on primary human Kupffer cells and monocytes in a TLR2- and PI3K-dependent manner (Tu et al.,; Zhai et al., ). In accordance, the PD-L1 levels on monocytes from HCV-infected patients were significantly higher than on monocytes from healthy individuals (Zhai et al., ). A recent study has shown that extracellular vesicles (EVs) produced by HBV-infected hepatocytes are endocytosed by circulating monocytes resulting in PD-L1 upregulation (Huang et al.,; Kakizaki et al., ). Moreover, PD-L1 and PD-L2 are upregulated by hantaviral N protein most likely via hantavirus-induced TLR3 signaling (Raftery et al., ). In addition, the latency-associated transcripts (LATs) of herpes simplex virus type 1 (HSV-1) upregulate PD-L1 on mouse neuroblastoma cells by an unknown mechanism (Chentoufi et al., ). Remarkably, as of yet no viral immunoevasin has been discovered that directly interacts with the molecules of the PD-1/PD-L1 axis to exploit its immunosuppressive function.

13Viral replication can also result in the production of anti-inflammatory cytokines such as IL-10 (Brooks et al.,; Ejrnaes et al., ). Cellular IL-10 has been shown to upregulate the expression of PD-1 and PD-L1 in a STAT-3 dependent manner in DCs and monocytes (Curiel et al.,; Selenko-Gebauer et al.,; Sun et al.,; Lamichhane et al., ). Accordingly, the absence of cellular IL-10 in LCMV infected mice results in enhanced effector T cell responses, rapid virus elimination, and generation of antiviral memory T cells (Brooks et al.,; Ejrnaes et al., ). Intriguingly, during coevolution with their hosts members of the virus family Herpesviridae have acquired numerous genes from their hosts including those that mimic cellular IL-10 (Raftery et al.,; Ouyang et al.,; Schonrich et al., ). These viral IL-10 (vIL-10) molecules act as immunosuppressive cytokines that also paralyze co-stimulatory B7 molecules (Muller et al.,; Raftery et al., ). It is possible that vIL-10 molecules also increase signaling through the PD-1/PD-L1 axis similar to their cellular counterparts thereby contributing to viral persistence. However, combined blockade of both, IL-10 and PD-L1, during chronic LCMV infection enhances T-cell function more efficiently than a single blockade (Brooks et al., ). Thus, IL-10 is pleiotropic and has immunosuppressive functions independent of the PD-1/PD-L1 axis during persisting virus infections (Ouyang et al., ).

14In the late phase of acute virus infection, type II IFN and several other cytokines including TNF-α and IL-10 are released by immune cells such as CD8+ T cell cells (Zhang and Bevan, ). IFN-γ strongly upregulates PD-L1 (Garcia-Diaz et al.,; Raftery et al.,; Sun et al., ). In addition, plasmacytoid DCs (pDCs) migrate into virus-infected tissue and secrete large amounts of type I IFNs (Siegal et al., ). These cytokines not only induce antiviral ISGs but also drive inflammatory responses such as secretion of TNF-α, IL-1β, or IL-6 (Davidson et al., ), which can further increase PD-L1 on various cell types including endothelial cells and at the same time promote non-lytic virus elimination (Sun et al., ). Thus, in the late phase of acute viral infection, PD-L1 is strongly upregulated thereby downregulating terminal differentiation of CD8+ T cells and preventing excessive tissue damage due to uncontrolled cytotoxic attack.

Function of PD-L1 During Acute Virus Infections

15PD-L1 expressed on hematopoietic or non-hematopoietic cells has different functions (Keir et al.,; Mueller et al., ). For example, PD-L1 expression on parenchymal cells of the pancreas rather than hematopoietic cells prevent autoimmune diabetes (Keir et al., ). In accordance, during LCMV infection of mice PD-L1 expression on non-hematopoietic cells reduces viral clearance and immunopathology (Keir et al., ). Thus, upregulation of PD-L1 expression may protect virus-infected cells from being eliminated by cytotoxic CD8+ T cells. On the other hand, selective absence of PD-L1 on hematopoietic cells results in lethal immunopathology (Mueller et al., ). This is best explained by an increase in number and function of cytotoxic CD8+ T lymphocytes, which may overwhelm the PD-L1-conferred protection in non-hematopoietic target cells (Frebel et al., ).

16Virus-induced PD-L1 on professional APCs may help to focus the antiviral CD8+ T cell response on a few strongly stimulatory, i.e., immunodominant, virus-derived epitopes by increasing the threshold of CD8+ T cell activation. In this way, the majority of weakly immunogenic viral peptides fail to activate CD8+ T cells. The adjustment of the “rheostat” on professional APCs may be necessary to prevent autoimmune disease and maintain peripheral tolerance in the face of a highly inflammatory milieu. Indeed, a recent study has shown that the PD-L1/PD-1 axis regulates T cell responses at the activation stage (Sugiura et al., ). CD80, which binds to CD28 and CTLA-4 on T cells, also interacts with PD-L1 (Butte et al.,, ). Importantly, this interaction occurs only in cis (Chaudhri et al., ) and prevents PD-L1 on DCs from co-inhibitory signaling to T cells via PD-1 (Chaudhri et al.,; Sugiura et al., ). In contrast, the functions of CD28 (co-stimulatory) and CTLA-4 (co-inhibitory) are not impaired by cis-PD-L1/CD80 interactions on DCs (Sugiura et al., ). Many viruses upregulate PD-L1 on professional APCs such as DCs (Table 1) either directly or through IFN release. Low PD-L1 levels on uninfected DCs have only a weak impact on T cell activation (Brown et al., ) due to cis-PD-L1/CD80 interactions (Figure 1, upper scheme). It is likely, that the high PD-L1 levels on DCs in the context of viral infection will overwhelm the cis-binding capacity of CD80 resulting in increased co-inhibitory signaling via PD-1 (Figure 1, lower scheme). PD-L1 on professional APCs also promotes the induction and maintenance of regulatory T cells (Treg cells; Francisco et al., ). Treg cells help to confine the antiviral defense and to prevent immunopathology during virus infections (Veiga-Parga et al., ). Taken together, viruses can reprogram DC function in antiviral immune responses by tipping the balance between co-inhibitory and co-stimulatory signals as shown for murine cytomegalovirus (Loewendorf et al.,; Benedict et al., ) and vaccinia virus (Kleinpeter et al., ).

17Strong stimulation of the PD-1/PD-L1 does not prevent immunopathology during viral hemorrhagic fever (VHF). VHF is a designation for distinct but pathogenically similar zoonotic diseases that are caused by several enveloped RNA viruses including Ebola virus (EBOV), hantavirus, and dengue virus (DENV) (Paessler and Walker, ). VHF viruses target endothelial cells thereby causing vascular leakage (Zampieri et al.,; Schonrich et al.,; Basler, ). In fact, type III IFN and TNF-α, which upregulate PD-L1 on endothelial cells, also mediate dysfunction of the endothelial barrier (Brett et al.,; Koh et al., ). Virus-specific CD8+ T cells show high levels of PD-1 on the surface during acute infection with EBOV (McElroy et al., ). Moreover, fatal EBOV infection is characterized by a high percentage of T cells expressing PD-1 and other co-inhibitory receptors such as CTLA-4 (Ruibal et al., ). Monocytes are susceptible to EBOV infection and upregulate production of PD-L1 transcripts in response to EBOV replication (Menicucci et al., ), whereas DENV-infected DCs express higher levels of PD-L2 but reduced PD-L1 (Nightingale et al., ). In patients with acute hantavirus infection large amounts of soluble PD-L1/PD-L2 are found in the sera indicating that these molecules are strongly upregulated in hantavirus-infected cells in vivo (Raftery et al., ). In accordance, strongly increased PD-L1 levels are detected after hantavirus infection of immature DCs in vitro and in hantavirus-infected mice with a humanized immune system (Raftery et al., ). In striking contrast, CD8+ T cells do not upregulate PD-1 during acute hantavirus infection (Lindgren et al., ).

18Taken together, in the acute phase of viral infection virus-specific T cells rapidly upregulate the co-inhibitory receptor PD-1 upon recognition of antigen. Simultaneously, viruses upregulate PD-L1 on hematopoietic and non-hematopoietic cells directly through PRR signaling or indirectly by inducing the release of IFNs and other inflammatory cytokines. Ideally, a tailor-made antiviral CD8+ T cell response eliminates viral pathogens with minimal immunopathology (Figure 2). The antiviral immune response during VHF, however, eliminates viruses at the cost of vascular leakage. The dysregulation of the immune responses could be due to variations in PD-L1 expression (e.g., timing, cell type, or strength), imbalance between co-stimulatory vs. co-inhibitory receptors (failure of “checks and balances”), or altered usage of PD-L1 interaction partners (PD-1, CD80, and possibly additional unknown partners). On the other hand viruses can also manipulate the “checks and balances” of the immune system in such a way that an effective antiviral immune response is prevented helping the pathogen to persist in the organism.

Chronic Virus Infection

19Chronic infections with viruses such as hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) represent major causes of chronic disease and death worldwide (Ott et al.,; Schweitzer et al.,;,; Stanaway et al., ). During chronic infection virus particles are continuously released from virus-infected cells and maintain a network of immunosuppressive mechanisms that interfere with virus elimination (Ng et al., ). Therefore, T cells enter a state called T cell exhaustion.

T Cell Exhaustion and Partial Restoration of T Cell Function by Blockade of the PD-1/PD-L1 Axis

20The first evidence for T cell exhaustion was gathered in paradigmatic experiments using LCMV-infected mice (Zehn and Wherry,; Kahan and Zajac, ). Derivatives of LCMV Arm and LCMV WE (LCMV clone13 and LCMV docile, respectively) vigorously replicate and disseminate in mice thereby persisting for more than 100 days (Moskophidis et al.,; Gallimore et al.,; Zajac et al., ). In this model of chronic virus infection, CD4+ T cells are crucial to sustain the virus-specific CD8+ T cell responses (Matloubian et al., ). Sustained upregulation of PD-1 and other co-inhibitory receptors such as 2B4, CTLA-4, and lymphocyte-activation gene 3 (Lag3) has become the defining characteristic of exhausted T (Tex) cells (Barber et al.,; Wherry et al.,; Blackburn et al.,; Crawford et al., ). These phenotypic changes are accompanied by a multistep loss of T cell effector functions (Speiser et al.,; Kahan et al.,; Wherry and Kurachi,; McKinney and Smith, ). Dependent on the strength of PD-1 signaling CD8+ T lymphocytes gradually lose important effector functions (Wherry et al.,; Wei et al., ). Some are lost early (such as cytotoxicity, IL-2 production, and proliferation), whereas others (e.g., IFN-γ production) are maintained for a longer time (Wherry et al.,; Wei et al., ). Finally, Tex cells undergo apoptosis (Kahan et al., ). As an underlying mechanism of T cell exhaustion during chronic LCMV infection, PD-1 signaling impairs T cell motility facilitating engagement of inhibitory pathways in T cells (Zinselmeyer et al., ). In another experimental setting, PD-L1 blocking antibodies prolong the T cell migration arrest suggesting that PD-1 signaling in fact enhances T cell motility (Honda et al., ). The reason for these contrasting results are unclear at the moment. Intriguingly, PD-1-regulated changes in several metabolic pathways occur at the very beginning of Tex cell development underlining the importance of these metabolic processes in the execution of the Tex program (Bengsch et al.,; Schurich et al.,;McKinney and Smith, ).

21Several reports have found differences in the transcriptional program and epigenetic profile of Tex cells as compared to memory and effector T lymphocytes (Wherry et al.,; Doering et al.,; Pauken et al., ). In Tex cells derived from LCMV-infected mice, the Pdcd1 regulatory region is completely demethylated and remains so even when virus titers decrease (Youngblood et al., ). They do not show antigen-independent persistence driven by IL-7 and IL-15, the hallmark of memory T cells, and instead require the continuous presence of their cognate antigen (Wherry and Ahmed,; Shin et al., ). This can be explained by the observation that the TCR-induced transcription factors IRF4, BATF, and NFATc1 not only drive T cell exhaustion but also impair memory T cell development during chronic LCMV infection (Man et al., ). Recently, microRNA (miR)-155 has been identified as a key molecule that promotes long-term persistence of Tex cells (Stelekati et al., ).

22T cells that have been rendered dysfunctional during persisting virus infections can be reinvigorated (Brooks et al., ). Blockade of the PD-1/PD-L1 axis during chronic LCMV infection reinvigorates antiviral T cell functions and reduces viral load (Barber et al., ). Of note, CD8+ T cells also become exhausted in the absence of PD-1 (Odorizzi et al., ). These experiments show that other coinhibitory receptors contribute to T cell exhaustion. In line with this view, a combined blockade of PD-1 and LAG-3 or PD-1 and Tim-3 synergistically improves antiviral CD8+ T cell responses and viral control in mice with chronic LCMV infection (Blackburn et al.,; Jin et al., ). Reinvigorated CD8+ T cells in chronically LCMV-infected mice become exhausted again after termination of the PD-L1 blockade (Pauken et al.,; Sen et al.,; Turner and Russ, ). This finding indicates that inflexibility of the epigenetic regulation in Tex cells may limit the success of therapies using ICIs.

23The studies of chronic LCMV infection in mice also relate to important human infectious diseases. In a recently established mouse model of HCV infection Tex cells are observed in the liver of mice infected with a newly identified Norway rat hepacivirus (NrHV), which belong to the same virus family as HCV (Billerbeck et al.,; Klenerman and Barnes, ). In NrHV-infected mice, CD4+ T cells were important to maintain the antiviral CD8+ T cell response similar to the LCMV model of chronic virus infection (Billerbeck et al., ). Blockade of the PD-1/PD-L1 axis in early chronic infection reduced the viral load whereas no beneficial effects were observed at later time points (Billerbeck et al., ). Moreover, ICIs blocking the PD-1 pathway can reinvigorate to some extent Tex cells in humans chronically infected with HBV or HCV (McKinney and Smith,; Cox et al.,; Saeidi et al.,; Wykes and Lewin, ). Targeting the PD-1/PD-L1 pathway during retroviral infections has beneficial effects for virus control (Velu et al., ). PD-1 upregulation is linked to a loss of function in HIV-specific CD8+ T cells, which can be partially reversed in vitro by a blockade of the PD-1/PD-L1 axis (Day et al.,; Trautmann et al., ). Surprisingly, the context and timing of PD-1 blockade seems to be important for its functional outcome: PD-1 signaling inhibition during stimulation of naive CD8+ T cells results in diminished activation, whereas PD-1 blockade during the T cell effector phase increases activation (Garcia-Bates et al., ). PD-1 blockade in rhesus macaques infected with simian immunodeficiency (SIV) rapidly increases the number and functional quality of virus-specific CD8+ T cells (Velu et al., ). Intriguingly, the combination of anti-PD-1 antibodies and antiretroviral therapy further improves antiviral CD8+ T cell function in SIV-infected rhesus macaques (Mylvaganam et al., ). This observation implies that directly acting antivirals (DAAs) reducing the viral load and ICIs releasing the brake in Tex cells synergistically increase antiviral T cell responses.

24Recent data suggest that PD-1 expression does not necessarily reflect T cell failure but rather adaption of T cell function to chronic inflammation (Utzschneider et al.,,; Speiser et al.,; Staron et al.,; Zehn et al.,; Barnes,; Petrelli et al., ). In fact, at least two CD8+ Tex cell subsets exist that act in concert to mount a partially effective CD8+ T cell response for control of chronic virus infection (Paley et al., ). Moreover, Tex cells have the capacity for self-renewal and are not entirely functionally inactive (Paley et al., ). The latter finding implies that Tex cells may represent a form of antiviral defense that is evolutionary adapted to the need to control a chronically replicating non-lytic virus with minimal collateral tissue damage and immunopathology. Moreover, experiments in mice with genetic ablation of PD-1 suggest that PD-1 is not required for induction of Tex cells (Odorizzi et al., ). In fact, PD-1 may play a pivotal role in maintaining Tex cells by preventing excessive stimulation that leads to proliferation and terminal differentiation (Odorizzi et al., ). After the elimination of HCV by DAAs, PD-1 expressing CD8+ T cell populations remain that display characteristics of memory cells including antigen-independent survival and proliferation after re-challenge with antigen (Wieland et al., ).

Latent Infection and Reactivation

25Viruses that establish latent infection include the members of the family Herpesviridae. In contrast to chronic infection, latent infection is characterized by periodic suspension of virus replication. However, the blueprint of viral particles is preserved in the latently infected host cells enabling the virus to reactivate and resume virus production. It is a matter of debate whether reactivation from latent virus infection creates enough antigenic load to induce exhaustion of antiviral CD8+ T cells. Memory CD8+ T cells recognizing viral antigens in the context of chronic virus infections (e.g., HIV) more frequently express PD-1 than memory CD8+ T cells stimulated by virus periodically reactivating from latency, e.g., human cytomegalovirus (HCMV) (Petrovas et al., ). This finding is consistent with the idea that the amount of available antigen regulates PD-1 expression on reactive T cells (Petrovas et al., ). In accordance, increased virus replication in immunosuppressed patients with HCMV disease after allogeneic hematopoietic cell transplantation is associated with PD-1 upregulation on T cells (Gallez-Hawkins et al., ). In mice with a humanized immune system, HCMV reactivations induced by granulocyte-colony stimulating factor (G-CSF) resulted in a shift toward PD-1 expressing T cells (Theobald et al., ). Whether this phenotype corresponds to Tex cells is unclear, however. Upregulation of co-inhibitory receptors such as PD-1 on CD8+ T cells is tightly linked to activation and differentiation and not per se proof of T cell exhaustion (Legat et al., ). In addition, studies of HSV-1 infection in mice did not reveal evidence for functional impairment of virus-specific CD8+ T cells during latency and subsequent reactivations (Mackay et al., ).

26PD-1 expression on brain Trm cells is maintained independently from antigen (Shwetank et al., ). Recently, it has been shown that Trm cells provide immunosurveillance in the human brain to eliminate neurotropic viruses (Smolders et al., ). In accordance, reactivation of HSV-1 from latently infected neurons of the mouse is controlled by CD8+ Trm lymphocytes (Liu et al.,; Khanna et al.,; Verjans et al., ). These immune cells provide IFN-γ which upregulates PD-L1 on HSV-1-infected neurons (Jeon et al., ). CD8+ T cells recognizing subdominant epitopes derived from HSV-1 proteins other than glycoprotein B (gB) but not CD8+ T cells specific for the dominant gB-derived epitope show a partial exhausted phenotype with increased PD-1 expression (Jeon et al., ). Blockade of PD-L1 resulted in increased survival of exhausted CD8+ T cells that were non-functional and not protective, however (Jeon et al., ). In contrast, it has been reported that HSV-1 LATs promotes functional exhaustion of CD8+ T cells specific for the dominant gB-derived epitope (Allen et al.,; Chentoufi et al., ).

27During coevolution with their host, herpesviruses developed numerous mechanisms to evade the antiviral immune response such as modulation of programmed cell death (Raftery et al.,,; Muller et al.,; Kather et al., ) and downregulation of MHC class I molecules (Schuren et al., ). Intriguingly, replication competent varicella-zoster virus (VZV) downregulates MHC class I and PD-L1 molecules in human brain vascular adventitial fibroblasts, perineurial cells, and human lung fibroblasts (Jones et al., ). In contrast, VZV upregulates PD-L1 in hematopoietic cells (Jones et al., ). The mechanism underlying VZV-associated downregulation of PD-L1 is posttranscriptional in nature but the VZV-encoded protein responsible has not yet been identified (Jones et al., ). VZV might target PD-L1 to increase the migration arrest of T cells (Honda et al., ). In this way, the virus could more efficiently spread from lung fibroblasts to T cells, which play crucial role in VZV dissemination to the skin (Arvin et al., ).

Concluding Remarks

28It is a seductive proposition that a virus induces PD-1 ligands in order to inhibit and thus evade the host immune response. On the other hand, recent data on the regulation of PD-L1 expression during viral infection suggest that PD-L1 upregulation is rather a part of the normal innate response induced by IFNs and PRR signaling. The reason for this is still enigmatic. PD-L1 may have a yet not defined immunostimulatory role in the very early phase of viral infection. Later, it may adjust the quantity and quality of the antiviral CD8+ T cell response in such a way that virus is eliminated with minimal collateral tissue damage. The PD-1/PD-L1 axis may also be important to maintain antiviral Trm cells and Tex cells. Virus-induced PD-1 ligand expression as an immune evasion strategy should always be rigorously tested with this in mind.

Author Contributions

29All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

Conflict of Interest Statement

30The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 220

1.
Abdelsamed H. A. Moustaki A. Fan Y. Dogra P. Ghoneim H. E. Youngblood B. (2017 ). Human memory CD8 T cell effector potential is epigenetically preserved during in vivo homeostasis. J. Exp. Med. 214, 1593–1606.
Not in our library10.1084/jem.20161760
2.
Agata Y. Kawasaki A. Nishimura H. Ishida Y. Tsubata T. Yagita H.. (1996 ). Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765–772.
Not in our library10.1093/intimm/8.5.765
3.
Ahn E. Araki K. Hashimoto M. Li W. Riley J. L. Cheung J.. (2018 ). Role of PD-1 during effector CD8 T cell differentiation. Proc. Natl. Acad. Sci. U.S.A. 115, 4749–4754.
Not in our library10.1073/pnas.1718217115
4.
Aichele P. Unsoeld H. Koschella M. Schweier O. Kalinke U. Vucikuja S. (2006 ). CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. J. Immunol. 176, 4525–4529.
Not in our library10.4049/jimmunol.176.8.4525
5.
Akhmetzyanova I. Drabczyk M. Neff C. P. Gibbert K. Dietze K. K. Zelinskyy G. (2015 ). PD-L1 expression on retrovirus-infected cells mediates immune escape from CD8+ T cell killing. PLoS Pathog. 11:e1005224
Not in our library10.1371/journal.ppat.1005224
6.
Akondy R. S. Fitch M. Edupuganti S. Yang S. Kissick H. T. Ahmed R. (2017 ). Origin and differentiation of human memory CD8 T cells after vaccination. Nature 552, 362–367.
Not in our library10.1038/nature24633
7.
Allen S. J. Hamrah P. Gate D. Mott K. R. Mantopoulos D. Ghiasi H. (2011 ). The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. J. Virol. 85, 4184–4197.
Not in our library10.1128/jvi.02290-10
8.
Interferon-λs: Front-Line Guardians of Immunity and Homeostasis in the Respiratory Tract · 2017
Not checked
9.
Ariotti S. Hogenbirk M. A. Dijkgraaf F. E. Visser L. L. Hoekstra M. E. Schumacher T. N. (2014 ). Skin-resident memory CD8(+) T cells trigger a state of tissue-wide pathogen alert. Science 346, 101–105.
Not in our library10.1126/science.1254803
10.
Arvin A. M. Moffat J. F. Sommer M. Oliver S Che X. Vleck S.. (2010 ). Varicella-zoster virus T cell tropism and the pathogenesis of skin infection. Curr. Top. Microbiol. Immunol. 342, 189–209.
Not in our library10.1007/82_2010_29
11.
Attanasio J. Wherry E. J. (2016 ). Costimulatory and coinhibitory receptor pathways in infectious disease. Immunity 44, 1052–1068.
Not in our library10.1016/j.immuni.2016.04.022
12.
Barber D. L. Wherry E. J. Masopust D. Zhu B. Allison J. P. Ahmed R. (2006 ). Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682–687.
Not in our library10.1038/nature04444
13.
Barnes E. (2018 ). Unravelling the fate of functional PD1+ T cells in chronic viral hepatitis. J. Clin. Invest. 128, 573–576.
Not in our library10.1172/jci99035
14.
Basler C. F. (2017 ). Molecular pathogenesis of viral hemorrhagic fever. Semin. Immunopathol. 39, 551–561.
Not in our library10.1007/s00281-017-0637-x
15.
Benedict C. A. Loewendorf A. Garcia Z. Blazar B. R. Janssen E. M. (2008 ). Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway. J. Immunol. 180, 4836–4847.
Not in our library10.4049/jimmunol.180.7.4836
16.
Bengsch B. Johnson A. L. Kurachi M. Odorizzi P. M. Pauken K. E. Attanasio J.. (2016 ). Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion. Immunity 45, 358–373.
Not in our library10.1016/j.immuni.2016.07.008
17.
Billerbeck E. Wolfisberg R. Fahnoe U. Xiao J. W. Quirk C. Rice C. M. (2017 ). Mouse models of acute and chronic hepacivirus infection. Science 357, 204–208.
Not in our library10.1126/science.aal1962
18.
Biron C. A. Nguyen K. B. Pien G. C. (2002 ). Innate immune responses to LCMV infections: natural killer cells and cytokines. Curr. Top. Microbiol. Immunol. 263, 7–27.
Not in our library10.1007/978-3-642-56055-2_2
19.
Blackburn S. D. Shin H. Haining W. N. Zou T. Workman C. J. Wherry E. J. (2009 ). Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29–37.
Not in our library10.1038/ni.1679
20.
Blattman J. N. Wherry E. J. Ha S. J. van der Most R. G. Ahmed R. (2009 ). Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection. J. Virol. 83, 4386–4394.
Not in our library10.1128/jvi.02524-08
21.
Boasso A. Hardy A. W. Landay A. L. Martinson J. L. Anderson S. A. Shearer G. M. (2008 ). PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes. Clin. Immunol. 129, 132–144.
Not in our library10.1016/j.clim.2008.05.009
22.
Boes M. Meyer-Wentrup F. (2015 ). TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells. Cancer Lett. 361, 49–56.
Not in our library10.1016/j.canlet.2015.02.027
23.
Brett J. Gerlach H. Nawroth P. Steinberg S. Godman G. Stern D. (1989 ). Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J. Exp. Med. 169, 1977–1991.
Not in our library10.1084/jem.169.6.1977
24.
Brooks D. G. Ha S. J. Elsaesser H. Sharpe A. H. Freeman G. J. Oldstone M. B. (2008 ). IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc. Natl. Acad. Sci. U.S.A. 105, 20428–20433.
Not in our library10.1073/pnas.0811139106
25.
Brooks D. G. McGavern D. B. Oldstone M. B. (2006a ). Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection. J. Clin. Invest. 116, 1675–1685.
Not in our library10.1172/jci26856
26.
Brooks D. G. Trifilo M. J. Edelmann K. H. Teyton L. McGavern D. B. Oldstone M. B. (2006b ). Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 12, 1301–1309.
Not in our library10.1038/nm1492
27.
Brown J. A. Dorfman D. M. Ma F. R. Sullivan E. L. Munoz O. Freeman G. J. (2003 ). Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170, 1257–1266.
Not in our library10.4049/jimmunol.170.3.1257
28.
Brown K. E. Freeman G. J. Wherry E. J. Sharpe A. H. (2010 ). Role of PD-1 in regulating acute infections. Curr. Opin. Immunol. 22, 397–401.
Not in our library10.1016/j.coi.2010.03.007
29.
Butte M. J. Keir M. E. Phamduy T. B. Sharpe A. H. Freeman G. J. (2007 ). Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27, 111–122.
Not in our library10.1016/j.immuni.2007.05.016
30.
Butte M. J. Pena-Cruz V. Kim M. J. Freeman G. J. Sharpe A. H. (2008 ). Interaction of human PD-L1 and B7-1. Mol. Immunol. 45, 3567–3572.
Not in our library10.1016/j.molimm.2008.05.014
31.
Carbone F. R. Gebhardt T. (2014 ). A neighborhood watch upholds local immune protection. Science 346, 40–41.
Not in our library10.1126/science.1259925
32.
Channappanavar R. Twardy B. S. Suvas S. (2012 ). Blocking of PDL-1 interaction enhances primary and secondary CD8 T cell response to herpes simplex virus-1 infection. PLoS ONE 7:e39757.
Not in our library10.1371/journal.pone.0039757
33.
Chaudhri A. Xiao Y. Klee A. N. Wang X. Zhu B. Freeman G. J. (2018 ). PD-L1 binds to B7-1 only in Cis on the same cell surface. Cancer Immunol. Res. 6, 921–929.
Not in our library10.1158/2326-6066.cir-17-0316
34.
Chen L. Flies D. B. (2013 ). Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227–242.
Not in our library10.1038/nri3405
35.
Chentoufi A. A. Kritzer E. Tran M. V. Dasgupta G. Lim C. H. BenMohamed L. (2011 ). The herpes simplex virus 1 latency-associated transcript promotes functional exhaustion of virus-specific CD8+ T cells in latently infected trigeminal ganglia: a novel immune evasion mechanism. J. Virol. 85, 9127–9138.
Not in our library10.1128/jvi.00587-11
36.
Chikuma S. Terawaki S. Hayashi T. Nabeshima R. Yoshida T. Shibayama S.. (2009 ). PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J. Immunol. 182, 6682–6689.
Not in our library10.4049/jimmunol.0900080
37.
Cole J. E. Navin T. J. Cross A. J. Goddard M. E. Alexopoulou L. Monaco C. (2011 ). Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc. Natl. Acad. Sci. U.S.A. 108, 2372–2377.
Not in our library10.1073/pnas.1018515108
38.
Cox M. A. Nechanitzky R. Mak T. W. (2017 ). Check point inhibitors as therapies for infectious diseases. Curr. Opin. Immunol. 48, 61–67.
Not in our library10.1016/j.coi.2017.07.016
39.
Crawford A. Angelosanto J. M. Kao C. Doering T. A. Odorizzi P. M. Wherry E. J. (2014 ). Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity 40, 289–302.
Not in our library10.1016/j.immuni.2014.01.005
40.
Curiel T. J. Wei S. Dong H. Alvarez X. Cheng P. Zou W. (2003 ). Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9, 562–567.
Not in our library10.1038/nm863
41.
David P. Megger D. A. Kaiser T. Werner T. Liu J. Zelinskyy G. (2019 ). The PD-1/PD-L1 pathway affects the expansion and function of cytotoxic CD8(+) T cells during an acute retroviral infection. Front. Immunol. 10:54.
Not in our library10.3389/fimmu.2019.00054
42.
Disease-Promoting Effects of Type I Interferons in Viral, Bacterial, and Coinfections · 2015
No notice
43.
Day C. L. Kaufmann D. E. Kiepiela P. Brown J. A. Moodley E. S. Walker B. D. (2006 ). PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350–354.
Not in our library10.1038/nature05115
44.
Doering T. A. Crawford A. Angelosanto J. M. Paley M. A. Ziegler C. G. Wherry E. J. (2012 ). Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity 37, 1130–1144.
Not in our library10.1016/j.immuni.2012.08.021
45.
Ejrnaes M. Filippi C. M. Martinic M. M. Ling E. M. Togher L. M. von Herrath M. G. (2006 ). Resolution of a chronic viral infection after interleukin-10 receptor blockade. J. Exp. Med. 203, 2461–2472.
Not in our library10.1084/jem.20061462
46.
Erickson J. J. Gilchuk P. Hastings A. K. Tollefson S. J. Johnson M. Williams J. V. (2012 ). Viral acute lower respiratory infections impair CD8+ T cells through PD-1. J. Clin. Invest. 122, 2967–2982.
Not in our library10.1172/jci62860
47.
Esensten J. H. Helou Y. A. Chopra G. Weiss A. Bluestone J. A. (2016 ). CD28 costimulation: from mechanism to therapy. Immunity 44, 973–988.
Not in our library10.1016/j.immuni.2016.04.020
48.
Fife B. T. Pauken K. E. (2011 ). The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann. N. Y. Acad. Sci. 1217, 45–59.
Not in our library10.1111/j.1749-6632.2010.05919.x
49.
Francisco L. M. Sage P. T. Sharpe A. H. (2010 ). The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236, 219–242.
Not in our library10.1111/j.1600-065x.2010.00923.x
50.
Francisco L. M. Salinas V. H. Brown K. E. Vanguri V. K. Freeman G. J. Sharpe A. H. (2009 ). PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206, 3015–3029.
Not in our library10.1084/jem.20090847
51.
Frebel H. Nindl V. Schuepbach R. A. Braunschweiler T. Richter K. Oxenius A. (2012 ). Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J. Exp. Med. 209, 2485–2499.
Not in our library10.1084/jem.20121015
52.
Galani I. E. Triantafyllia V. Eleminiadou E. E. Koltsida O. Stavropoulos A. Andreakos E. (2017 ). Interferon-lambda mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness. Immunity 46, 875–890 e6.
Not in our library10.1016/j.immuni.2017.04.025
53.
Gallez-Hawkins G. M. Thao L. Palmer J. Dagis A. Li X. Zaia J. A. (2009 ). Increased programmed death-1 molecule expression in cytomegalovirus disease and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 15, 872–880.
Not in our library10.1016/j.bbmt.2009.03.022
54.
Gallimore A. Glithero A. Godkin A. Tissot A. C. Pluckthun A. Zinkernagel R. (1998 ). Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. 187, 1383–1393.
Not in our library10.1084/jem.187.9.1383
55.
Gamradt P. Laoubi L. Nosbaum A. Mutez V. Lenief V. Grande S. (2019 ). Inhibitory checkpoint receptors control CD8(+) resident memory T cells to prevent skin allergy. J. Allergy Clin. Immunol. 2019:48
Not in our library10.1016/j.jaci.2018.11.048
56.
Garcia-Bates T. M. Palma M. L. Shen C. Gambotto A. Macatangay B. J. C. Mailliard R. B. (2019 ). Contrasting roles of the PD-1 signaling pathway in dendritic cell-mediated induction and regulation of HIV-1-specific effector T cell functions. J. Virol. 93:5.
Not in our library10.1128/jvi.02035-18
57.
Garcia-Diaz A. Shin D. S. Moreno B. H. Saco J. Escuin-Ordinas H. Ribas A. (2017 ). Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19, 1189–1201.
Not in our library10.1016/j.celrep.2017.04.031
58.
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015 · 2016
No notice
59.
Gebhardt T. Wakim L. M. Eidsmo L. Reading P. C. Heath W. R. Carbone F. R. (2009 ). Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat. Immunol. 10, 524–530.
Not in our library10.1038/ni.1718
60.
Good C. Wells A. I. Coyne C. B. (2019 ). Type III interferon signaling restricts enterovirus 71 infection of goblet cells. Sci. Adv. 5:eaau4255.
Not in our library10.1126/sciadv.aau4255
61.
Grakoui A. John Wherry E. Hanson H. L. Walker C. Ahmed R. (2006 ). Turning on the off switch: regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. J. Hepatol. 45, 468–472.
Not in our library10.1016/j.jhep.2006.07.009
62.
Gupta N. Hegde P. Lecerf M. Nain M. Kaur M. Kalia M.. (2014 ). Japanese encephalitis virus expands regulatory T cells by increasing the expression of PD-L1 on dendritic cells. Eur. J. Immunol. 44, 1363–1374.
Not in our library10.1002/eji.201343701
63.
Hashimoto M. Kamphorst A. O. Im S. J. Kissick H. T. Pillai R. N. Ahmed R. (2018 ). CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu. Rev. Med. 69, 301–318.
Not in our library10.1146/annurev-med-012017-043208
64.
Hombrink P. Helbig C. Backer R. A. Piet B. Oja A. E. van Lier R. A. (2016 ). Programs for the persistence, vigilance and control of human CD8(+) lung-resident memory T cells. Nat. Immunol. 17, 1467–1478.
Not in our library10.1038/ni.3589
65.
Honda T. Egen J. G. Lammermann T. Kastenmuller W. Torabi-Parizi P. Germain R. N. (2014 ). Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues. Immunity 40, 235–247.
Not in our library10.1016/j.immuni.2013.11.017
66.
Host K. M. Jacobs S. R. West J. A. Zhang Z. Costantini L. M. Damania B. (2017 ). Kaposi's sarcoma-associated herpesvirus increases PD-L1 and proinflammatory cytokine expression in human monocytes. MBio 8:5.
Not in our library10.1128/mbio.00917-17
67.
Huang Z. Y. Xu P. Li J. H. Zeng C. H. Song H. F. Wang X. F. (2017 ). Clinical significance of dynamics of programmed death ligand-1 expression on circulating CD14(+) monocytes and CD19(+) B cells with the progression of hepatitis B virus infection. Viral Immunol. 30, 224–231.
Not in our library10.1089/vim.2016.0122
68.
Ishida Y. Agata Y. Shibahara K. Honjo T. (1992 ). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887–3895.
Not in our library10.1002/j.1460-2075.1992.tb05481.x
69.
Iwai Y. Terawaki S. Ikegawa M. Okazaki T. Honjo T. (2003 ). PD-1 inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med. 198, 39–50.
Not in our library10.1084/jem.20022235
70.
Jeon S. Rowe A. M. Carroll K. L. Harvey S. A. K. Hendricks R. L. (2018 ). PD-L1/B7-H1 inhibits viral clearance by macrophages in HSV-1-infected corneas. J. Immunol. 200, 3711–3719.
Not in our library10.4049/jimmunol.1700417
71.
Jeon S. St. Leger A. J. Cherpes T. L. Sheridan B. S. Hendricks R. L. (2013 ). PD-L1/B7-H1 regulates the survival but not the function of CD8+ T cells in herpes simplex virus type 1 latently infected trigeminal ganglia. J. Immunol. 190, 6277–6286.
Not in our library10.4049/jimmunol.1300582
72.
Jin H. T. Anderson A. C. Tan W. G. West E. E. Ha S. J. Ahmed R. (2010 ). Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. U.S.A. 107, 14733–14738.
Not in our library10.1073/pnas.1009731107
73.
Jones D. Blackmon A. Neff C. P. Palmer B. E. Gilden D. Nagel M. A. (2016 ). Varicella-zoster virus downregulates programmed death ligand 1 and major histocompatibility complex class I in human brain vascular adventitial fibroblasts, perineurial cells, and lung fibroblasts. J. Virol. 90, 10527–10534.
Not in our library10.1128/jvi.01546-16
74.
Jones D. Como C. N. Jing L. Blackmon A. Neff C. P. Nagel M. A. (2019 ). Varicella zoster virus productively infects human peripheral blood mononuclear cells to modulate expression of immunoinhibitory proteins and blocking PD-L1 enhances virus-specific CD8+ T cell effector function. PLoS Pathog. 15:e1007650.
Not in our library10.1371/journal.ppat.1007650
75.
Kahan S. M. Wherry E. J. Zajac A. J. (2015 ). T cell exhaustion during persistent viral infections. Virology 479–480, 180–193.
Not in our library10.1016/j.virol.2014.12.033
76.
Kahan S. M. Zajac A. J. (2019 ). Immune exhaustion: past lessons and new insights from lymphocytic choriomeningitis virus. Viruses 11:2.
Not in our library10.3390/v11020156
77.
Kakizaki M. Yamamoto Y. Yabuta S. Kurosaki N. Kagawa T. Kotani A. (2018 ). The immunological function of extracellular vesicles in hepatitis B virus-infected hepatocytes. PLoS ONE 13:e0205886.
Not in our library10.1371/journal.pone.0205886
78.
Kather A. Raftery M. J. Devi-Rao G. Lippmann J. Giese T. Schonrich G. (2010 ). Herpes simplex virus type 1 (HSV-1)-induced apoptosis in human dendritic cells as a result of downregulation of cellular FLICE-inhibitory protein and reduced expression of HSV-1 antiapoptotic latency-associated transcript sequences. J. Virol. 84, 1034–1046.
Not in our library10.1128/jvi.01409-09
79.
Keir M. E. Butte M. J. Freeman G. J. Sharpe A. H. (2008 ). PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704.
Not in our library10.1146/annurev.immunol.26.021607.090331
80.
Keir M. E. Liang S. C. Guleria I. Latchman Y. E. Qipo A. Sharpe A. H. (2006 ). Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203, 883–895.
Not in our library10.1084/jem.20051776
81.
Khanna K. M. Bonneau R. H. Kinchington P. R. Hendricks R. L. (2003 ). Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 18, 593–603.
Not in our library10.1016/s1074-7613(03)00112-2
82.
Kleinpeter P. Remy-Ziller C. Winter E. Gantzer M. Nourtier V. Kempf J. (2019 ). By binding CD80 and CD86, the vaccinia virus' M2 protein blocks their interactions with both CD28 and CTLA4 and potentiates CD80's binding to PD-L1. J. Virol. 2019:19
Not in our library10.1128/jvi.00207-19
83.
Klenerman P. Barnes E. J. (2017 ). Immunology taught by rats. Science 357, 129–130.
Not in our library10.1126/science.aao0184
84.
Koh K. P. Wang Y. Yi T. Shiao S. L. Lorber M. I. Pober J. S. (2004 ). T cell-mediated vascular dysfunction of human allografts results from IFN-gamma dysregulation of NO synthase. J. Clin. Invest. 114, 846–856.
Not in our library10.1172/jci21767
85.
Kolumam G. A. Thomas S. Thompson L. J. Sprent J. Murali-Krishna K. (2005 ). Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202, 637–650.
Not in our library10.1084/jem.20050821
86.
Kumar B. V. Ma W. Miron M. Granot T. Guyer R. S. Farber D. L. (2017 ). Human tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites. Cell Rep. 20, 2921–2934.
Not in our library10.1016/j.celrep.2017.08.078
87.
Lafon M. Megret F. Meuth S. G. Simon O. Velandia Romero M. L. Wiendl H. (2008 ). Detrimental contribution of the immuno-inhibitor B7-H1 to rabies virus encephalitis. J. Immunol. 180, 7506–7515.
Not in our library10.4049/jimmunol.180.11.7506
88.
Lamichhane P. Karyampudi L. Shreeder B. Krempski J. Bahr D. Daum J.. (2017 ). IL10 Release upon PD-1 blockade sustains immunosuppression in ovarian cancer. Cancer Res. 77, 6667–6678.
Not in our library10.1158/0008-5472.can-17-0740
89.
Lazear H. M. Schoggins J. W. Diamond M. S. (2019 ). Shared and distinct functions of type I and type III interferons. Immunity 50, 907–923.
Not in our library10.1016/j.immuni.2019.03.025
90.
Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than “Exhaustion” of Human CD8 T Cells · 2013
No notice
91.
Lindgren T. Ahlm C. Mohamed N. Evander M. Ljunggren H. G. Bjorkstrom N. K. (2011 ). Longitudinal analysis of the human T cell response during acute hantavirus infection. J. Virol. 85, 10252–10260.
Not in our library10.1128/jvi.05548-11
92.
Liu T. Khanna K. M. Chen X. Fink D. J. Hendricks R. L. (2000 ). CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J. Exp. Med. 191, 1459–1466.
Not in our library10.1084/jem.191.9.1459
93.
Loewendorf A. Kruger C. Borst E. M. Wagner M. Just U. Messerle M. (2004 ). Identification of a mouse cytomegalovirus gene selectively targeting CD86 expression on antigen-presenting cells. J. Virol. 78, 13062–13071.
Not in our library10.1128/jvi.78.23.13062-13071.2004
94.
Loke P. Allison J. P. (2003 ). PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. U.S.A. 100, 5336–5341.
Not in our library10.1073/pnas.0931259100
95.
Mackay L. K. Wakim L. van Vliet C. J. Jones C. M. Mueller S. N. Carbone F. R. (2012 ). Maintenance of T cell function in the face of chronic antigen stimulation and repeated reactivation for a latent virus infection. J. Immunol. 188, 2173–2178.
Not in our library10.4049/jimmunol.1102719
96.
Maier H. Isogawa M. Freeman G. J. Chisari F. V. (2007 ). PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J. Immunol. 178, 2714–2720.
Not in our library10.4049/jimmunol.178.5.2714
97.
Man K. Gabriel S. S. Liao Y. Gloury R. Preston S. Kallies A. (2017 ). Transcription factor IRF4 promotes CD8(+) T cell exhaustion and limits the development of memory-like T cells during chronic infection. Immunity 47, 1129–1141 e5.
Not in our library10.1016/j.immuni.2017.11.021
98.
Masopust D. Choo D. Vezys V. Wherry E. J. Duraiswamy J. Ahmed R. (2010 ). Dynamic T cell migration program provides resident memory within intestinal epithelium. J. Exp. Med. 207, 553–564.
Not in our library10.1084/jem.20090858
99.
Matloubian M. Concepcion R. J. Ahmed R. (1994 ). CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J. Virol. 68, 8056–8063.
Not in our library10.1128/jvi.68.12.8056-8063.1994
100.
Matloubian M. Somasundaram T. Kolhekar S. R. Selvakumar R. Ahmed R. (1990 ). Genetic basis of viral persistence: single amino acid change in the viral glycoprotein affects ability of lymphocytic choriomeningitis virus to persist in adult mice. J. Exp. Med. 172, 1043–1048.
Not in our library10.1084/jem.172.4.1043
101.
McElroy A. K. Akondy R. S. Davis C. W. Ellebedy A. H. Mehta A. K. Ahmed R. (2015 ). Human Ebola virus infection results in substantial immune activation. Proc. Natl. Acad. Sci. U.S.A. 112, 4719–4724.
Not in our library10.1073/pnas.1502619112
102.
McKendry R. T. Spalluto C. M. Burke H. Nicholas B. Cellura D. Wilkinson T. M. (2016 ). Dysregulation of antiviral function of CD8(+) T cells in the chronic obstructive pulmonary disease lung. Role of the PD-1-PD-L1 Axis. Am. J. Respir. Crit. Care Med. 193, 642–651.
Not in our library10.1164/rccm.201504-0782oc
103.
McKinney E. F. Smith K. G. (2016 ). T cell exhaustion and immune-mediated disease-the potential for therapeutic exhaustion. Curr. Opin. Immunol. 43, 74–80.
Not in our library10.1016/j.coi.2016.09.005
104.
McKinney E. F. Smith K. G. C. (2018 ). Metabolic exhaustion in infection, cancer and autoimmunity. Nat. Immunol. 19, 213–221.
Not in our library10.1038/s41590-018-0045-y
105.
McNally B. Ye F. Willette M. Flano E. (2013 ). Local blockade of epithelial PDL-1 in the airways enhances T cell function and viral clearance during influenza virus infection. J. Virol. 87, 12916–12924.
Not in our library10.1128/jvi.02423-13
106.
Meier A. Bagchi A. Sidhu H. K. Alter G. Suscovich T. J. Altfeld M. (2008 ). Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. AIDS 22, 655–658.
Not in our library10.1097/qad.0b013e3282f4de23
107.
Menicucci A. R. Versteeg K. Woolsey C. Mire C. E. Geisbert J. B. Messaoudi I. (2017 ). Transcriptome analysis of circulating immune cell subsets highlight the role of monocytes in zaire ebola virus makona pathogenesis. Front. Immunol. 8:1372.
Not in our library10.3389/fimmu.2017.01372
108.
Moskophidis D. Lechner F. Pircher H. Zinkernagel R. M. (1993 ). Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362, 758–761.
Not in our library10.1038/362758a0
109.
Mueller S. N. Vanguri V. K. Ha S. J. West E. E. Keir M. E. Ahmed R. (2010 ). PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J. Clin. Invest. 120, 2508–2515.
Not in our library10.1172/jci40040
110.
Muhlbauer M. Fleck M. Schutz C. Weiss T. Froh M. Blank C.. (2006 ). PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J. Hepatol. 45, 520–528.
Not in our library10.1016/j.jhep.2006.05.007
111.
Muller A. Schmitt L. Raftery M. Schonrich G. (1998 ). Paralysis of B7 co-stimulation through the effect of viral IL-10 on T cells as a mechanism of local tolerance induction. Eur. J. Immunol. 28, 3488–3498.
Not in our library10.1002/(sici)1521-4141(199811)28:11<3488::aid-immu3488>3.0.co;2-y
112.
Muller D. B. Raftery M. J. Kather A. Giese T. Schonrich G. (2004 ). Frontline: Induction of apoptosis and modulation of c-FLIPL and p53 in immature dendritic cells infected with herpes simplex virus. Eur. J. Immunol. 34, 941–951.
Not in our library10.1002/eji.200324509
113.
Mylvaganam G. H. Chea L. S. Tharp G. K. Hicks S. Velu V. Amara R. R. (2018 ). Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV. JCI Insight 3:18.
Not in our library10.1172/jci.insight.122940
114.
Ng C. T. Snell L. M. Brooks D. G. Oldstone M. B. (2013 ). Networking at the level of host immunity: immune cell interactions during persistent viral infections. Cell Host Microbe 13, 652–664.
Not in our library10.1016/j.chom.2013.05.014
115.
Nightingale Z. D. Patkar C. Rothman A. L. (2008 ). Viral replication and paracrine effects result in distinct, functional responses of dendritic cells following infection with dengue 2 virus. J. Leukoc. Biol. 84, 1028–1038.
Not in our library10.1189/jlb.0208105
116.
Nishimura H. Nose M. Hiai H. Minato N. Honjo T. (1999 ). Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141–151.
Not in our library10.1016/s1074-7613(00)80089-8
117.
Nishimura H. Okazaki T. Tanaka Y. Nakatani K. Hara M. Matsumori A.. (2001 ). Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319–322.
Not in our library10.1126/science.291.5502.319
118.
Odorizzi P. M. Pauken K. E. Paley M. A. Sharpe A. Wherry E. J. (2015 ). Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J. Exp. Med. 212, 1125–1137.
Not in our library10.1084/jem.20142237
119.
Okabayashi T. Kojima T. Masaki T. Yokota S. Imaizumi T. Tsutsumi H. (2011 ). Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res. 160, 360–366.
Not in our library10.1016/j.virusres.2011.07.011
120.
Okazaki T. Chikuma S. Iwai Y. Fagarasan S. Honjo T. (2013 ). A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat. Immunol. 14, 1212–1218.
Not in our library10.1038/ni.2762
121.
Okazaki T. Honjo T. (2006 ). The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27, 195–201.
Not in our library10.1016/j.it.2006.02.001
122.
Omilusik K. D. Goldrath A. W. (2017 ). The origins of memory T cells. Nature 552, 337–339.
Not in our library10.1038/d41586-017-08280-8
123.
Ong E. Z. Chan K. R. Ooi E. E. (2016 ). Viral manipulation of host inhibitory receptor signaling for immune evasion. PLoS Pathog. 12:e1005776.
Not in our library10.1371/journal.ppat.1005776
124.
Ott J. J. Stevens G. A. Groeger J. Wiersma S. T. (2012 ). Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30, 2212–2219.
Not in our library10.1016/j.vaccine.2011.12.116
125.
Ouyang P. Rakus K. van Beurden S. J. Westphal A. H. Davison A. J. Vanderplasschen A. F. (2014 ). IL-10 encoded by viruses: a remarkable example of independent acquisition of a cellular gene by viruses and its subsequent evolution in the viral genome. J. Gen. Virol. 95(Pt 2), 245–262.
Not in our library10.1099/vir.0.058966-0
126.
Ouyang W. Rutz S. Crellin N. K. Valdez P. A. Hymowitz S. G. (2011 ). Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 29, 71–109.
Not in our library10.1146/annurev-immunol-031210-101312
127.
Paessler S. Walker D. H. (2013 ). Pathogenesis of the viral hemorrhagic fevers. Annu. Rev. Pathol. 8, 411–440.
Not in our library10.1146/annurev-pathol-020712-164041
128.
Paley M. A. Kroy D. C. Odorizzi P. M. Johnnidis J. B. Dolfi D. V. Wherry E. J. (2012 ). Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338, 1220–1225.
Not in our library10.1126/science.1229620
129.
IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection · 2017
No notice
130.
Pauken K. E. Sammons M. A. Odorizzi P. M. Manne S. Godec J. Wherry E. J. (2016 ). Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354, 1160–1165.
Not in our library10.1126/science.aaf2807
131.
Petrelli A. Mijnheer G. van Konijnenburg D. P. H. van der Wal M. M. Giovannone B. Mocholi E. (2018 ). PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation. J. Clin. Invest. 2018:6107
Not in our library10.1172/jci96107
132.
Petrovas C. Casazza J. P. Brenchley J. M. Price D. A. Gostick E. Koup R. A. (2006 ). PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J. Exp. Med. 203, 2281–2292.
Not in our library10.1084/jem.20061496
133.
Planes R. BenMohamed L. Leghmari K. Delobel P. Izopet J. Bahraoui E. (2014 ). HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms. J. Virol. 88, 6672–6689.
Not in our library10.1128/jvi.00825-14
134.
Probst H. C. McCoy K. Okazaki T. Honjo T. van den Broek M. (2005 ). Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 6, 280–286.
Not in our library10.1038/ni1165
135.
Pulko V. Liu X. Krco C. J. Harris K. J. Frigola X. Dong H. (2009 ). TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J. Immunol. 183, 3634–3641.
Not in our library10.4049/jimmunol.0900974
136.
Raftery M. Muller A. Schonrich G. (2000 ). Herpesvirus homologues of cellular genes. Virus Genes 21, 65–75.
Not in our library10.1023/a:1008184330127
137.
Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism · 2018
Not checked
138.
Raftery M. J. Behrens C. K. Muller A. Krammer P. H. Walczak H. Schonrich G. (1999 ). Herpes simplex virus type 1 infection of activated cytotoxic T cells: induction of fratricide as a mechanism of viral immune evasion. J. Exp. Med. 190, 1103–1114.
Not in our library10.1084/jem.190.8.1103
139.
Raftery M. J. Schwab M. Eibert S. M. Samstag Y. Walczak H. Schonrich G. (2001 ). Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity 15, 997–1009.
Not in our library10.1016/s1074-7613(01)00239-4
140.
Raftery M. J. Wieland D. Gronewald S. Kraus A. A. Giese T. Schonrich G. (2004 ). Shaping phenotype, function, and survival of dendritic cells by cytomegalovirus-encoded IL-10. J. Immunol. 173, 3383–3391.
Not in our library10.4049/jimmunol.173.5.3383
141.
Rodriguez-Garcia M. Porichis F. de Jong O. G. Levi K. Diefenbach T. J. Kavanagh D. G. (2011 ). Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. J. Leukoc. Biol. 89, 507–515.
Not in our library10.1189/jlb.0610327
142.
Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo · 2018
Not checked
143.
Ruibal P. Oestereich L. Ludtke A. Becker-Ziaja B. Wozniak D. M. Munoz-Fontela C. (2016 ). Unique human immune signature of Ebola virus disease in Guinea. Nature 533, 100–104.
Not in our library10.1038/nature17949
144.
Rutigliano J. A. Sharma S. Morris M. Y. Oguin T. H. III. McClaren J. L. Thomas P. G. (2014 ). Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells. J. Virol. 88, 1636–1651.
Not in our library10.1128/jvi.02851-13
145.
T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses · 2018
No notice
146.
Sallusto F. Lenig D. Forster R. Lipp M. Lanzavecchia A. (1999 ). Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708–712.
Not in our library10.1038/44385
147.
Sanmamed M. F. Chen L. (2018 ). A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175, 313–326.
Not in our library10.1016/j.cell.2018.09.035
148.
Schenkel J. M. Fraser K. A. Beura L. K. Pauken K. E. Vezys V. Masopust D. (2014 ). Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science 346, 98–101.
Not in our library10.1126/science.1254536
149.
Schenkel J. M. Fraser K. A. Vezys V. Masopust D. (2013 ). Sensing and alarm function of resident memory CD8(+) T cells. Nat. Immunol. 14, 509–513.
Not in our library10.1038/ni.2568
150.
Schonrich G. Abdelaziz M. O. Raftery M. J. (2017 ). Herpesviral capture of immunomodulatory host genes. Virus Genes 53, 762–773.
Not in our library10.1007/s11262-017-1460-0
151.
Schonrich G. Rang A. Lutteke N. Raftery M. J. Charbonnel N. Ulrich R. G. (2008 ). Hantavirus-induced immunity in rodent reservoirs and humans. Immunol. Rev. 225, 163–189.
Not in our library10.1111/j.1600-065x.2008.00694.x
152.
Schuren A. B. Costa A. I. Wiertz E. J. (2016 ). Recent advances in viral evasion of the MHC Class I processing pathway. Curr. Opin. Immunol. 40, 43–50.
Not in our library10.1016/j.coi.2016.02.007
153.
Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 T Cells in the Same Host · 2016
No notice
154.
Schweitzer A. Horn J. Mikolajczyk R. T. Krause G. Ott J. J. (2015 ). Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386, 1546–1555.
Not in our library10.1016/s0140-6736(15)61412-x
155.
Selenko-Gebauer N. Majdic O. Szekeres A. Hofler G. Guthann E. Korthauer U.. (2003 ). B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J. Immunol. 170, 3637–3644.
Not in our library10.4049/jimmunol.170.7.3637
156.
Sen D. R. Kaminski J. Barnitz R. A. Kurachi M. Gerdemann U. Haining W. N. (2016 ). The epigenetic landscape of T cell exhaustion. Science 354, 1165–1169.
Not in our library10.1126/science.aae0491
157.
Shaabani N. Duhan V. Khairnar V. Gassa A. Ferrer-Tur R. Haussinger D.. (2016 ). CD169(+) macrophages regulate PD-L1 expression via type I interferon and thereby prevent severe immunopathology after LCMV infection. Cell Death Dis. 7:e2446.
Not in our library10.1038/cddis.2016.350
158.
Sharpe A. H. Pauken K. E. (2018 ). The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153–167.
Not in our library10.1038/nri.2017.108
159.
Sharpe A. H. Wherry E. J. Ahmed R. Freeman G. J. (2007 ). The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8, 239–245.
Not in our library10.1038/ni1443
160.
Shin H. (2018 ). Formation and function of tissue-resident memory T cells during viral infection. Curr. Opin. Virol. 28, 61–67.
Not in our library10.1016/j.coviro.2017.11.001
161.
Shin H. Blackburn S. D. Blattman J. N. Wherry E. J. (2007 ). Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. J. Exp. Med. 204, 941–949.
Not in our library10.1084/jem.20061937
162.
Shwetank Abdelsamed H. A. Frost E. L. Schmitz H. M. Mockus T. E. Youngblood B. A.. (2017 ). Maintenance of PD-1 on brain-resident memory CD8 T cells is antigen independent. Immunol. Cell Biol. 95, 953–959.
Not in our library10.1038/icb.2017.62
163.
Siegal F. P. Kadowaki N. Shodell M. Fitzgerald-Bocarsly P. A. Shah K. Liu Y. J. (1999 ). The nature of the principal type 1 interferon-producing cells in human blood. Science 284, 1835–1837.
Not in our library10.1126/science.284.5421.1835
164.
Tissue-resident memory T cells populate the human brain · 2018
No notice
165.
Speiser D. E. Utzschneider D. T. Oberle S. G. Munz C. Romero P. Zehn D. (2014 ). T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat. Rev. Immunol. 14, 768–774.
Not in our library10.1038/nri3740
166.
Stanaway J. D. Flaxman A. D. Naghavi M. Fitzmaurice C. Vos T. Abubakar I.. (2016 ). The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388, 1081–1088.
Not in our library10.1016/s0140-6736(16)30579-7
167.
Stanciu L. A. Bellettato C. M. Laza-Stanca V. Coyle A. J. Papi A. Johnston S. L. (2006 ). Expression of programmed death-1 ligand (PD-L) 1, PD-L2, B7-H3, and inducible costimulator ligand on human respiratory tract epithelial cells and regulation by respiratory syncytial virus and type 1 and 2 cytokines. J. Infect. Dis. 193, 404–412.
Not in our library10.1086/499275
168.
Staples K. J. Nicholas B. McKendry R. T. Spalluto C. M. Wallington J. C. Wilkinson T. M. (2015 ). Viral infection of human lung macrophages increases PDL1 expression via IFNbeta. PLoS ONE 10:e0121527.
Not in our library10.1371/journal.pone.0121527
169.
Staron M. M. Gray S. M. Marshall H. D. Parish I. A. Chen J. H. Kaech S. M. (2014 ). The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity 41, 802–814.
Not in our library10.1016/j.immuni.2014.10.013
170.
Stelekati E. Chen Z. Manne S. Kurachi M. Ali M. A. Wherry E. J. (2018 ). Long-term persistence of exhausted CD8 T cells in chronic infection is regulated by microRNA-155. Cell Rep. 23, 2142–2156.
Not in our library10.1016/j.celrep.2018.04.038
171.
Sugiura D. Maruhashi T. Okazaki I. M. Shimizu K. Maeda T. K. Okazaki T. (2019 ). Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science 2019:7062
Not in our library10.1126/science.aav7062
172.
Sun C. Mezzadra R. Schumacher T. N. (2018 ). Regulation and function of the PD-L1 checkpoint. Immunity 48, 434–452.
Not in our library10.1016/j.immuni.2018.03.014
173.
Sun Z. Fourcade J. Pagliano O. Chauvin J. M. Sander C. Zarour H. M. (2015 ). IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells. Cancer Res. 75, 1635–1644.
Not in our library10.1158/0008-5472.can-14-3016
174.
Surh C. D. Sprent J. (2008 ). Homeostasis of naive and memory T cells. Immunity 29, 848–862.
Not in our library10.1016/j.immuni.2008.11.002
175.
Szabo P. A. Miron M. Farber D. L. (2019 ). Location, location, location: tissue resident memory T cells in mice and humans. Sci. Immunol. 4:34.
Not in our library10.1126/sciimmunol.aas9673
176.
Teijaro J. R. Ng C. Lee A. M. Sullivan B. M. Sheehan K. C. Welch M.. (2013 ). Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340, 207–211.
Not in our library10.1126/science.1235214
177.
Telcian A. G. Laza-Stanca V. Edwards M. R. Harker J. A. Wang H. Johnston S. L. (2011 ). RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell nonspecific antiviral activity. J. Infect. Dis. 203, 85–94.
Not in our library10.1093/infdis/jiq020
178.
Terawaki S. Chikuma S. Shibayama S. Hayashi T. Yoshida T. Okazaki T.. (2011 ). IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J. Immunol. 186, 2772–2779.
Not in our library10.4049/jimmunol.1003208
179.
Theobald S. J. Khailaie S. Meyer-Hermann M. Volk V. Olbrich H. Stripecke R. (2018 ). Signatures of T and B cell development, functional responses and PD-1 upregulation after HCMV latent infections and reactivations in Nod.Rag.gamma mice humanized with cord blood CD34(+) cells. Front. Immunol. 9:2734.
Not in our library10.3389/fimmu.2018.02734
180.
Trautmann L. Janbazian L. Chomont N. Said E. A. Gimmig S. Sekaly R. P. (2006 ). Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198–1202.
Not in our library10.1038/nm1482
181.
Tsuda M. Matsumoto K. Inoue H. Matsumura M. Nakano T. Mori A.. (2005 ). Expression of B7-H1 and B7-DC on the airway epithelium is enhanced by double-stranded RNA. Biochem. Biophys. Res. Commun. 330, 263–270.
Not in our library10.1016/j.bbrc.2005.02.161
182.
Tu Z. Pierce R. H. Kurtis J. Kuroki Y. Crispe I. N. Orloff M. S. (2010 ). Hepatitis C virus core protein subverts the antiviral activities of human Kupffer cells. Gastroenterology 138, 305–314.
Not in our library10.1053/j.gastro.2009.09.009
183.
Turner S. J. Russ B. E. (2016 ). Can T cells be too exhausted to fight back? Science 354, 1104–1105.
Not in our library10.1126/science.aal3204
184.
Utzschneider D. T. Alfei F. Roelli P. Barras D. Chennupati V. Zehn D. (2016 ). High antigen levels induce an exhausted phenotype in a chronic infectiwithout impairing T cell expansion and survival. J. Exp. Med. 213, 1819–1834.
Not in our library10.1084/jem.20150598
185.
Utzschneider D. T. Legat A. Fuertes Marraco S. A. Carrie L. Luescher I. Zehn D. (2013 ). T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat. Immunol. 14, 603–610.
Not in our library10.1038/ni.2606
186.
Valero-Pacheco N. Arriaga-Pizano L. Ferat-Osorio E. Mora-Velandia L. M. Pastelin-Palacios R. Lopez-Macias C. (2013 ). PD-L1 expression induced by the 2009 pandemic influenza A(H1N1) virus impairs the human T cell response. Clin. Dev. Immunol. 2013:989673.
Not in our library10.1155/2013/989673
187.
Veiga-Parga T. Sehrawat S. Rouse B. T. (2013 ). Role of regulatory T cells during virus infection. Immunol. Rev. 255, 182–196.
Not in our library10.1111/imr.12085
188.
Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options · 2015
No notice
189.
Velu V. Titanji K. Zhu B. Husain S. Pladevega A. Lai L.. (2009 ). Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458, 206–210.
Not in our library10.1038/nature07662
190.
Verjans G. M. Hintzen R. Q. van Dun J. M. Poot A. Milikan J. C. Osterhaus A. D. (2007 ). Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc. Natl. Acad. Sci. U.S.A. 104, 3496–3501.
Not in our library10.1073/pnas.0610847104
191.
Virgin H. W. Wherry E. J. Ahmed R. (2009 ). Redefining chronic viral infection. Cell 138, 30–50.
Not in our library10.1016/j.cell.2009.06.036
192.
Wack A. Terczynska-Dyla E. Hartmann R. (2015 ). Guarding the frontiers: the biology of type III interferons. Nat. Immunol. 16, 802–809.
Not in our library10.1038/ni.3212
193.
Wakim L. M. Waithman J. van Rooijen N. Heath W. R. Carbone F. R. (2008 ). Dendritic cell-induced memory T cell activation in nonlymphoid tissues. Science 319, 198–202.
Not in our library10.1126/science.1151869
194.
Wang J. Yoshida T. Nakaki F. Hiai H. Okazaki T. Honjo T. (2005 ). Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc. Natl. Acad. Sci. U.S.A. 102, 11823–11828.
Not in our library10.1073/pnas.0505497102
195.
Wang X. Zhang Z. Zhang S. Fu J. Yao J. Jiao Y.. (2008 ). B7-H1 up-regulation impairs myeloid DC and correlates with disease progression in chronic HIV-1 infection. Eur. J. Immunol. 38, 3226–3236.
Not in our library10.1002/eji.200838285
196.
Wei F. Zhong S. Ma Z. Kong H. Medvec A. Ahmed R.. (2013 ). Strength of PD-1 signaling differentially affects T-cell effector functions. Proc. Natl. Acad. Sci. U.S.A. 110, E2480–E2489.
Not in our library10.1073/pnas.1305394110
197.
Welsh R. M. Seedhom M. O. (2008 ). Lymphocytic choriomeningitis virus (LCMV): propagation, quantitation, and storage. Curr. Protoc. Microbiol. 15A:1
Not in our library10.1002/9780471729259.mc15a01s8
198.
Wherry E. J. Ahmed R. (2004 ). Memory CD8 T-cell differentiation during viral infection. J. Virol. 78, 5535–5545.
Not in our library10.1128/jvi.78.11.5535-5545.2004
199.
Wherry E. J. Barber D. L. Kaech S. M. Blattman J. N. Ahmed R. (2004 ). Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc. Natl. Acad. Sci. U.S.A. 101, 16004–16009.
Not in our library10.1073/pnas.0407192101
200.
Wherry E. J. Blattman J. N. Murali-Krishna K. van der Most R Ahmed R. (2003 ). Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911–4927.
Not in our library10.1128/jvi.77.8.4911-4927.2003
201.
Wherry E. J. Ha S. J. Kaech S. M. Haining W. N. Sarkar S. Ahmed R. (2007 ). Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27, 670–684.
Not in our library10.1016/j.immuni.2007.09.006
202.
Wherry E. J. Kurachi M. (2015 ). Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486–499.
Not in our library10.1038/nri3862
203.
TCF1+ hepatitis C virus-specific CD8+ T cells are maintained after cessation of chronic antigen stimulation · 2017
No notice
204.
Wilson E. B. Yamada D. H. Elsaesser H. Herskovitz J. Deng J. Cheng G.. (2013 ). Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340, 202–207.
Not in our library10.1126/science.1235208
205.
Wolchok J. (2018 ). Putting the immunologic brakes on cancer. Cell 175, 1452–1454.
Not in our library10.1016/j.cell.2018.11.006
206.
Wu X. Wu P. Shen Y. Jiang X. Xu F. (2018 ). CD8(+) resident memory T cells and viral infection. Front. Immunol. 9:2093.
Not in our library10.3389/fimmu.2018.02093
207.
Wykes M. N. Lewin S. R. (2018 ). Immune checkpoint blockade in infectious diseases. Nat. Rev. Immunol. 18, 91–104.
Not in our library10.1038/nri.2017.112
208.
Xiao Y. Yu S. Zhu B. Bedoret D. Bu X. Francisco L.. (2014 ). RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J. Exp. Med. 211, 943–959.
Not in our library10.1084/jem.20130790
209.
Xu H. Wang X. Pahar B. Moroney-Rasmussen T. Alvarez X. Lackner A.. (2010 ). Increased B7-H1 expression on dendritic cells correlates with programmed death 1 expression on T cells in simian immunodeficiency virus-infected macaques and may contribute to T cell dysfunction and disease progression. J. Immunol. 185, 7340–7348.
Not in our library10.4049/jimmunol.1001642
210.
Yamazaki T. Akiba H. Iwai H. Matsuda H. Aoki M. Tanno Y. (2002 ). Expression of programmed death 1 ligands by murine T cells and AP. J. Immunol. 169, 5538–5545.
Not in our library10.4049/jimmunol.169.10.5538
211.
Youngblood B. Hale J. S. Kissick H. T. Ahn E. Xu X. Ahmed R. (2017 ). Effector CD8 T cells dedifferentiate into long-lived memory cells. Nature 552, 404–409.
Not in our library10.1038/nature25144
212.
Youngblood B. Oestreich K. J. Ha S. J. Duraiswamy J. Akondy R. S. Ahmed R. (2011 ). Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 35, 400–412.
Not in our library10.1016/j.immuni.2011.06.015
213.
Zajac A. J. Blattman J. N. Murali-Krishna K. Sourdive D. J. Suresh M. Ahmed R. (1998 ). Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205–2213.
Not in our library10.1084/jem.188.12.2205
214.
Zampieri C. A. Sullivan N. J. Nabel G. J. (2007 ). Immunopathology of highly virulent pathogens: insights from Ebola virus. Nat. Immunol. 8, 1159–1164.
Not in our library10.1038/ni1519
215.
Interferon (IFN)-λ Takes the Helm: Immunomodulatory Roles of Type III IFNs · 2017
Not checked
216.
Zehn D. Utzschneider D. T. Thimme R. (2016 ). Immune-surveillance through exhausted effector T-cells. Curr. Opin. Virol. 16, 49–54.
Not in our library10.1016/j.coviro.2016.01.002
217.
Zehn D. Wherry E. J. (2015 ). Immune memory and exhaustion: clinically relevant lessons from the LCMV model. Adv. Exp. Med. Biol. 850, 137–152.
Not in our library10.1007/978-3-319-15774-0_10
218.
Zhai N. Li H. Song H. Yang Y. Cui A. Li T.. (2017 ). Hepatitis C virus induces MDSCs-like monocytes through TLR2/PI3K/AKT/STAT3 signaling. PLoS ONE 12:e0170516.
Not in our library10.1371/journal.pone.0170516
219.
Zhang N. Bevan M. J. (2011 ). CD8(+) T cells: foot soldiers of the immune system. Immunity 35, 161–168.
Not in our library10.1016/j.immuni.2011.07.010
220.
Zinselmeyer B. H. Heydari S. Sacristan C. Nayak D. Cammer M. McGavern D. B. (2013 ). PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J. Exp. Med. 210, 757–774.
Not in our library10.1084/jem.20121416

Cited by papers we hold 4

PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment · 2023
No notice
The Role of PD-1 in Acute and Chronic Infection · 2020
No notice
T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis · 2020
No notice
Disharmonic Inflammatory Signatures in COVID-19: Augmented Neutrophils’ but Impaired Monocytes’ and Dendritic Cells’ Responsiveness · 2020
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.